Core Viewpoint - The collaboration between Rakovina Therapeutics and NanoPalm Ltd. aims to develop novel small-molecule oncology therapeutics, starting with the dual PARP-HDAC inhibitor kt-3283, utilizing NanoPalm's advanced pLNP delivery technology [1][2][3]. Group 1: Collaboration Details - A non-binding Letter of Intent (LOI) has been signed to form a joint venture for co-developing oncology therapeutics [1]. - The joint venture will focus on advancing kt-3283 through late preclinical development and early clinical studies, while also evaluating additional AI-derived drug candidates [6][15]. - The collaboration combines Rakovina's AI-enabled drug discovery engine with NanoPalm's self-targeting pLNP delivery system, enhancing therapeutic delivery precision and efficacy [2][4]. Group 2: Technology and Innovation - kt-3283 is a potent small-molecule inhibitor that targets PARP and HDAC, showing enhanced cytotoxicity in preclinical studies, particularly in Ewing sarcoma, breast, and ovarian cancer models [3]. - NanoPalm's pLNP technology, originally developed for gene therapy, improves tissue specificity and systemic tolerability, representing a strategic entry into oncology [4][5]. - The collaboration aims to leverage AI-assisted design to enhance the delivery profile of small-molecule therapies, creating a robust pipeline for future commercialization [6][8]. Group 3: Operational and Strategic Aspects - The joint venture will be based in Saudi Arabia, aligning with the Kingdom's National Biotechnology Strategy and aiming for global development and commercialization [8][11]. - Intellectual property arising from the collaboration will be jointly owned, with each party retaining rights to their respective background IP [9]. - The partners will co-fund the joint venture and pursue third-party investments, sharing ownership, risk, and potential upside equally [15].

Core Viewpoint - Rakovina Therapeutics and NanoPalm Ltd. have signed a non-binding Letter of Intent to form a joint venture aimed at co-developing novel small-molecule oncology therapeutics, starting with the drug kt3283, utilizing NanoPalm's advanced pLNP delivery technology [1][6]. Company Overview - Rakovina Therapeutics is a biopharmaceutical company focused on cancer therapies, leveraging AI-powered drug discovery technologies, including the proprietary Deep Docking™ platform [13]. - NanoPalm Ltd. is a Saudi-based biotechnology company specializing in AI-designed pLNP delivery systems for gene and drug therapies, originally developed for gene therapy applications [11][12]. Joint Venture Details - The joint venture will focus on advancing kt3283, a dual-function PARP-HDAC inhibitor, through late preclinical development and early clinical studies, while also evaluating additional AI-derived drug candidates [6][9]. - The collaboration will be based in Saudi Arabia, with a global development and commercialization mandate, marking the first pLNP-oncology-focused biotech initiative in the region [9][16]. Technology and Innovation - Rakovina's AI-enabled drug discovery engine can rapidly screen billions of molecules against cancer targets, while NanoPalm's pLNP technology enhances therapeutic delivery precision and efficacy [2][4]. - kt3283 has shown strong preclinical activity in Ewing sarcoma, breast, and ovarian cancer models, demonstrating enhanced cytotoxicity compared to existing PARP and HDAC inhibitors [3][4]. Strategic Goals - The partnership aims to create a robust pipeline of novel therapeutics, with plans for global licensing and commercialization opportunities as the development pipeline matures [6][9]. - The joint venture will adhere to international regulatory standards, including those of the FDA, SFDA, and EMA, ensuring compliance and facilitating market entry [9][10].

Core Insights - Rakovina Therapeutics Inc. is advancing cancer therapies through AI-powered drug discovery in collaboration with the University of British Columbia and the Vancouver Prostate Centre [1][2][5] Collaboration and Infrastructure - The partnership with UBC and the Vancouver Prostate Centre allows for compound testing and validation in a leading cancer research facility, enhancing the translation of scientific discoveries [2][5] - Rakovina's management team and scientific advisory board members hold dual roles at UBC and the Vancouver Prostate Centre, strengthening the collaboration [3] Key Personnel - Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina, serves as an Associate Professor at UBC and leads Molecular Pathology at the Vancouver Prostate Centre, bridging cancer biology with Rakovina's drug discovery programs [3] - Dr. Artem Cherkasov, AI and medicinal chemistry advisor, is a Senior Research Scientist at the Vancouver Prostate Centre and a Professor at UBC, known for developing the Deep Docking™ platform that accelerates drug discovery [4] Strategic Alignment - The company emphasizes strategic alignment with UBC's research excellence, leveraging infrastructure and expertise to advance next-generation cancer therapies [5] - Rakovina Therapeutics is focused on developing a pipeline of DNA-damage response inhibitors, aiming to advance drug candidates into human clinical trials in collaboration with pharmaceutical partners [6][7]

Core Insights - Rakovina Therapeutics Inc. has approved the grant of 540,000 stock options to consultants, employees, officers, and directors as part of its Long Term Incentive Plan [1] - Each stock option is exercisable for five years at a price of $0.70 per share, vesting in equal parts every six months over the next three years [2] - The company focuses on developing innovative cancer treatments using AI-powered drug discovery, specifically targeting DNA-damage response [3] Company Overview - Rakovina Therapeutics is a biopharmaceutical research company dedicated to advancing cancer therapies through unique technologies and proprietary generative AI platforms [3] - The company aims to optimize drug candidates at a faster pace and has established a pipeline of DNA-damage response inhibitors, with plans to advance candidates into human clinical trials in collaboration with pharmaceutical partners [3]

Core Viewpoint - Rakovina Therapeutics Inc. is implementing an early exercise warrant incentive program to encourage the exercise of up to 19,200,000 outstanding common share purchase warrants, aiming to enhance liquidity and shareholder engagement [1][3]. Summary by Sections Warrant Details - Each Eligible Warrant was originally exercisable for one common share at an exercise price of $0.20, which has been adjusted to $2.00 post a 10:1 share consolidation effective June 24, 2025 [2]. Incentive Program - The Incentive Program allows Eligible Warrant Holders to exercise their warrants at a reduced price of $0.75 per Warrant Share during a 30-day period from August 4, 2025, to September 2, 2025 [3]. - Eligible Warrant Holders can choose to exercise all, some, or none of their warrants, with no fractional Warrant Shares being issued [3]. Approval and Notification - The Incentive Program is subject to approval from the TSX Venture Exchange, and a notice will be sent to Eligible Warrant Holders detailing the program and exercise period [4]. Related Party Transaction - Jeffrey Bacha, a director and insider of the Company, is eligible to participate in the Incentive Program, which may be classified as a related party transaction under Multilateral Instrument 61-101 [5]. Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using AI-powered drug discovery, with a pipeline of DNA-damage response inhibitors aimed at advancing drug candidates into human clinical trials [6].

Compounds developed through collaboration with Variational AI show targeted activityVANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced meaningful progress in its AI-driven KT-5000AI program, advancing the development of precision ATR (Ataxia Telangiectasia and Rad3-rel ...

Core Insights - Rakovina Therapeutics Inc. has achieved DTC eligibility, allowing its shares to be electronically cleared and settled, which enhances liquidity and market accessibility for U.S. investors [1][2][3] Group 1: DTC Eligibility Impact - DTC eligibility streamlines trading for U.S. investors, removing barriers and reducing costs and processing times [2][3] - This development is expected to increase Rakovina's visibility and accessibility to a broader base of institutional and retail investors [3] Group 2: Strategic Growth and Corporate Developments - The company is advancing its preclinical programs and exploring strategic partnerships in AI-enhanced diagnostics and oncology therapeutics [4] - Additional corporate developments are anticipated as the company continues to execute its strategic roadmap [4] Group 3: Company Overview - Rakovina Therapeutics focuses on developing innovative cancer treatments using AI technologies, specifically targeting DNA-damage response through its proprietary platforms [5][6] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [6]

Core Insights - Rakovina Therapeutics Inc. has partnered with VariationalAI, which has been awarded the 2025 Emerging Company of the Year – Biotech by LifeSciencesBC, highlighting the significant progress and innovation in the biotechnology sector [1][2]. Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments utilizing AI technologies, specifically through its proprietary Deep-Docking™ platform [6][7]. - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [7]. Partnership and Technology - Since the partnership began in September 2024, VariationalAI has utilized its Enki™ generative AI platform to expedite the discovery of novel DNA damage response (DDR) kinase inhibitors, particularly the KT-5000 series [3]. - The collaboration has resulted in multiple structurally novel compounds with favorable drug-like properties, showing promise as brain-penetrant agents for challenging tumors [3][4]. Recognition and Future Outlook - The recognition of VariationalAI as Emerging Biotech Company of the Year underscores the transformative impact of AI in drug discovery and the strength of the collaboration with Rakovina [4]. - The company anticipates further advancements in its AI-powered discovery pipeline, aiming to identify novel drug candidates with increased speed and precision [4][6].

Core Insights - Rakovina Therapeutics Inc. is advancing cancer therapies through AI-powered drug discovery and has partnered with VariationalAI, which has been recognized as the 2025 Emerging Company of the Year – Biotech by LifeSciencesBC [1][2]. Group 1: Partnership and Innovation - VariationalAI has utilized its Enki™ generative AI platform to accelerate the discovery of novel DNA damage response (DDR) kinase inhibitors since partnering with Rakovina in September 2024 [3]. - The collaboration has led to the development of the KT-5000 series, a new generation of synthetic small-molecule candidates targeting DDR pathways, resulting in multiple structurally novel compounds with favorable drug-like properties [3]. - Early data indicates that these candidates may serve as effective brain-penetrant agents for challenging tumors, marking a significant advancement in Rakovina's AI-powered discovery pipeline [3]. Group 2: Company Overview - Rakovina Therapeutics focuses on innovative cancer treatments, leveraging unique technologies for targeting DNA-damage response powered by AI through its proprietary Deep-Docking™ platform [6]. - The company aims to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners, establishing a pipeline of distinctive DNA-damage response inhibitors [7].

Core Viewpoint - Rakovina Therapeutics Inc. plans to amend the terms of its outstanding convertible debentures and warrants, subject to approval from the TSX Venture Exchange and the requisite majority of holders [1][3]. Convertible Debenture Amendments - The company intends to amend its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000, issued on May 29, 2023 [2][3]. - Proposed amendments include extending the maturity date from November 29, 2025, to June 6, 2028, reducing the conversion price from $2.00 to $1.00 per common share, eliminating any redemption premium, and stipulating that interest accrued will be payable on the maturity date [7]. Warrant Amendments - The company plans to amend the terms of 19,200,000 outstanding common share purchase warrants, which were issued in a private placement between June 26, 2024, and July 26, 2024 [5][6]. - Proposed changes include reducing the exercise price from $2.00 to $0.75 per common share and shortening the term from three years to thirty days from the date of Exchange approval [6]. Related Party Transactions - Certain directors of the company hold a principal amount of $100,000 in convertible debentures, representing approximately 6.9% of the outstanding amount, which qualifies as a related party transaction [4]. - Director Jeffrey Bacha holds 100,000 warrants, approximately 0.5% of the outstanding warrants, also constituting a related party transaction [8]. Company Overview - Rakovina Therapeutics is a biopharmaceutical research company focused on developing innovative cancer treatments using unique technologies for targeting the DNA-damage response, powered by artificial intelligence [10].